Taconic Biosciences News

Taconic's Dr. Alexander Maue recently authored a follow-up article for International Biopharmaceutical Industry (IBI) to his original comment on how the microbiome can improve reproducibility and translatability of animal models. In part two, he elaborates on how the microbiome can impact drug efficacy and what types of mouse models are being developed to further immuno-oncology research. Read the complete article at: biopharmaceuticalmedia.com...  Read More

Recent research into the microbiome demonstrates that the composition of gut microbiota influences the development and progression of disease. However, more research is needed to fully strengthen this connection. Taconic's Dr. Alexander Maue recently authored an article for Drug Discovery World depicting the investment landscape of biotech and pharmaceutical companies in the microbiome field. Dr. Maue describes how the number of IPOs, mergers & acquisitions, collaborations, and...  Read More

SIOP is an important process for many companies, and of prime importance for mouse model generation. Taconic's Terry Receveur was recently featured in AALAS discussing this process, and how it supports the 3Rs of animal research: Replacement, Reduction, and Refinement. The goal of SIOP is to develop a plan for sales, production, inventory, new product development, strategic initiatives, and financials. Read the complete article at: aalas.org...  Read More

In a recent article for Drug Target Review, Taconic's Dr. Paul Volden emphasizes how humanized immune system (HIS) mouse models have enabled the development of numerous immunotherapies. HIS models contain human immune cells and can offer more translatability in drug discovery and development than genetically engineered models. There are now a wide-variety of humanized mice available from animal model vendors, including the severely immunodeficient CIEA NOG mouse...  Read More

Announces Preclinical COVID-19 Research Tools Rensselaer, NY — March 20, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces support for global COVID-19 research efforts via a new Coronavirus Toolkit featuring relevant models and services. Mouse models have been extensively used for research on the SARS-CoV virus, closely related to the new SARS-CoV-2 virus that causes COVID-19. Taconic offers many animal...  Read More

The concept of T cell exhaustion and the associated immune response has become a priority for immuno-oncology researchers. Taconic's Dr. Janell Richardson was recently interviewed by Nature Methods to elaborate on how mouse models are helping researchers understand the complex processes involved in tumor-immune system interactions. The tumor microenvironment, cytokine expression, and cross-talk between immune system cells all play vital roles in understanding more how tumors evade...  Read More

Genetic Engineering & Biotechnology News recently published an article discussing the progression of advanced animal models for drug development research efforts. To address these developing needs, Taconic's Dr. Michael Seiler describes the differences between traditional inbred models and genetically engineered humanized immune system mice. Multiple humanized mouse models have been created in recent years, enabling researchers to conduct advanced studies in mice with humanized immune systems. "Traditional...  Read More

Local Production of Critical Immuno-oncology Models Now Available in Europe Rensselaer, NY — February 14, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces its humanized immune system mice models are now being produced in Europe. Local production provides European drug discovery researchers with easier access to this critical oncology research tool. Humanized immune system mice enable drug discovery research by...  Read More

Expands and Broadens Taconic Biosciences' Immuno-oncology Portfolio Application Rensselaer, NY — January 31, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model. Immuno-oncology leverages the body's immune system to fight cancer, increasing the ability to target the disease. Animal models used in this therapeutic development include special mice,...  Read More

New State-of-the-Art Laboratories in Leverkusen, Germany Rensselaer, NY — January 13, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, opened a new model generation facility in Leverkusen, Germany. This location houses model generation services, replacing the previous Taconic site in Cologne, Germany. Custom genetically modified animal models are critical to the drug discovery process. Taconic leads the industry in providing model...  Read More